期刊文献+

胎儿生长受限孕妇血浆活化蛋白c抵抗与抗心磷脂抗体检测结果分析 被引量:5

Relationship between the activated protein C resistance and anticardiolipin antibodies in patients with fetal growth restriction
下载PDF
导出
摘要 目的:研究活化蛋白c抵抗(APCR)、抗心磷脂抗体(ACA)与胎儿生长受限(FGR)的相关性,并进一步探讨FGR患者APCR与ACA的关系。方法:采用APTT±APC法检测20例原因不明FGR患者(实验组)、35例正常待产妇(对照组)的APCsr;Elisa方法检测ACA-IgG、IgM滴度水平。结果:①实验组APCR阳性率60.0%,明显高于对照组(31.4%),P(0.05;②实验组ACA阳性率20.0%,对照组2.9%,差异有显著性;③APCR阳性组ACA阳性3例,阴性组ACA阳性2例,无显著差异。结论:APCR和ACA均是FGR的危险因素,但获得性APCR的发生并非ACA抑制蛋白c通路导致凝血异常及导致FGR形成的唯一通路。 Objective: To examine the activated protein C sensitive ratio and the presence of anticardiolipin antibodies in pregnancies complicating with fetal growth restriction to explore the mechanism of fetal growth restriction. Methods: An activated partial thromboplastin time (APTT) - based assay for APCsr and ELISA for ACA of 20 pregnancies with idiophathic fetal growth restriction and 35 normal pregnancies. Results: The incidence of APCR and ACA in FGR group was higher than normal pregnant women,, and the difference was significant ( P 〈 0. 05 ) . Conclusion: The presence of either activated protein C resistance or ACA may contribute to risk of fetal growth restriction. There is not a significant interaction between APCR and ACA in pregnancies with fetal growth restriction.
作者 冯梅 冯玲
出处 《中国妇幼保健》 CAS 北大核心 2008年第6期859-861,共3页 Maternal and Child Health Care of China
关键词 活化蛋白C抵抗 抗心磷脂抗体 胎儿生长受限 血栓形成 妊娠病理 Activated protein C resistance Anticardiolipin antibodies Fetal growth restriction Thrombophilia Obstetric pathologies
  • 相关文献

参考文献1

二级参考文献9

  • 1[1]Ament L. Factor Ⅴ Leiden: a review of the literature. J Perinat Neonatal Nurs 2003; 17:190-5.
  • 2[2]Cleary-Goldman J, Nakhuda GS, Zimmermarn RC, et al. The role of factor V Leiden mutation in recurrent pregnancy loss. J Am Med Womens Assoc 2003 ;58:165-72.
  • 3[3]Bloomenthal D, Delisle MF, Tessier F, et al. Obstetric implications of the factor Ⅴ leiden mutation: a review. Am J Perinatol 2002;19:37-47.
  • 4[4]Dahlback B, Carlsson M, Svensson PJ, et al. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
  • 5[5]Bertina RM, Koeleman PC, Koster T, et al. Mutation in blood coagnlation factor Ⅴ associated with resistance to activated protein C. Nature 1994;369:64-7.
  • 6[6]Preston FE, Rosendaal FR, Walker ZD, et al. Increased fetal loss in women with heritable thrombophillia. Lancet 1996;348:913-6.
  • 7[7]Tal J, Schliamser LM, Leibovitz Z, et al. A possible role for activated protein C resistance in patients with first and second trimestet pregnancy failure. Hum Reprod 1999; 14:1624-7.
  • 8[8]Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intraveassociated with antiphospholipid antibodies. Arthritis Rheum 2003;48:728-31.
  • 9[9]Younis JS, Ohel G, Brenner B, et al. The effect ofthrombophylaxis on pregnancy outcome in patients with recurrent pregn-ancy loss associated with factor Ⅴleiden mutation. BJOG 2000;107:415-9.

同被引文献30

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部